Tamiflu oral capsules used for the treatment of influenza had USA sales of approximately $403 million.
Natco Pharma has launched the first generic equivalent of Tamiflu oral capsules (Roche's trade name for Oseltamivir phosphate capsules), 30 mg, 45 mg and 75 mg through its marketing partner Alvogen in the US market.
Alvogen is launching today the first generic equivalent to oseltamivir phosphate (Tamiflu-Roche) in the United States.
According to IMS Health, Tamiflu oral capsules had U.S. sales of approximately USA $403 million for the 12 months ended December 2015.
In August this year, Natco Pharma received a final approval for its abbreviated new drug application (ANDA) for generic versions of Tamiflu oral capsules from the US Food and Drug Administration (FDA).
The share price of Natco Pharma increased 2.53 per cent on the bourses in early trades and is trading at Rs 599.5 on intra-day basis.